董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Andrew P. Hider Chief Executive Officer and Director and President 49 2980.52万美元 0.22 2026-05-05
Patricia B. Morrison Independent Director 66 36.16万美元 1.61 2026-05-05
David S. Wilkes Independent Director 69 36.68万美元 0.29 2026-05-05
Jeffrey A. Craig Independent Director 64 36.00万美元 1.08 2026-05-05
Brent Shafer Independent Director and Non-Executive Chair of the Board 68 391.96万美元 5.99 2026-05-05
William A. Ampofo II Independent Director 52 33.74万美元 1.03 2026-05-05
Amy A. Wendell Independent Director 64 35.50万美元 4.85 2026-05-05
Michael R. McDonnell Independent Director 62 未披露 0.18 2026-05-05
Nancy M. Schlichting Independent Director 72 39.36万美元 0.81 2026-05-05

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Andrew P. Hider Chief Executive Officer and Director and President 49 2980.52万美元 0.22 2026-05-05
James Borzi Executive Vice President and Chief Supply Chain Officer 63 未披露 未持股 2026-05-05
David S. Rosenbloom Executive Vice President and General Counsel 66 379.42万美元 19.96 2026-05-05
Reazur Rasul Executive Vice President and Group President, Healthcare Systems and Technologies 49 524.62万美元 27.23 2026-05-05
Anita Zielinski Interim CFO,Senior Vice President, Chief Accounting Officer and Controller 52 未披露 未持股 2026-05-05
Maria Cecilia Soriano Group President, Infusion Therapies & Technologies & Pharmaceuticals 54 265.48万美元 4.82 2026-05-05
Jeanne K. Mason Executive Vice President and Chief Human Resources Officer 70 414.36万美元 未持股 2026-05-05

董事简历

中英对照 |  中文 |  英文
Andrew P. Hider

Andrew P. Hider,他是ATS Corporation (TSX和NYSE: ATS)的首席执行官和董事会成员,分别自2017年3月和2017年5月担任该职位。此前,他曾担任Taylor Made Group, LLC的总裁兼首席执行官(2016年5月至2017年2月)。在此之前,他曾在Danaher Corporation任职10年,担任越来越重要的职务,最近担任Veeder Root的总裁。他的职业生涯始于General Electric,任职于多个领域,包括制造、项目管理、采购和财务。他目前还担任Tennant Company的董事会成员。他获得Clarkson大学的跨学科工程与管理学士学位和工商管理硕士学位。


Andrew P. Hider is President and Chief Executive Officer and a member of the Board of Directors of Baxter. He was appointed on Augt 19, 2025. Additionally, he was appointed as Interim Group President, Medical Products & Therapies, in October 2025 and served in that interim capacity until December 2025. Before joining Baxter, he served as Chief Executive Officer and a member of the board of directors of ATS Corporation, roles which he has held since March 2017 and May 2017, respectively. Previoly, Mr. Hider served as President and Chief Executive Officer of the Taylor Made Group, LLC, from May 2016 to February 2017. Prior to that, Mr. Hider served for ten years at Danaher Corporation, working in roles of increasing responsibility, most recently serving as President of Veeder Root. Mr. Hider began his career with General Electric, serving in a number of areas including manufacturing, project management, procurement and finance. He currently serves on the board of directors of Tennant Company (NYSE: TNC).
Andrew P. Hider,他是ATS Corporation (TSX和NYSE: ATS)的首席执行官和董事会成员,分别自2017年3月和2017年5月担任该职位。此前,他曾担任Taylor Made Group, LLC的总裁兼首席执行官(2016年5月至2017年2月)。在此之前,他曾在Danaher Corporation任职10年,担任越来越重要的职务,最近担任Veeder Root的总裁。他的职业生涯始于General Electric,任职于多个领域,包括制造、项目管理、采购和财务。他目前还担任Tennant Company的董事会成员。他获得Clarkson大学的跨学科工程与管理学士学位和工商管理硕士学位。
Andrew P. Hider is President and Chief Executive Officer and a member of the Board of Directors of Baxter. He was appointed on Augt 19, 2025. Additionally, he was appointed as Interim Group President, Medical Products & Therapies, in October 2025 and served in that interim capacity until December 2025. Before joining Baxter, he served as Chief Executive Officer and a member of the board of directors of ATS Corporation, roles which he has held since March 2017 and May 2017, respectively. Previoly, Mr. Hider served as President and Chief Executive Officer of the Taylor Made Group, LLC, from May 2016 to February 2017. Prior to that, Mr. Hider served for ten years at Danaher Corporation, working in roles of increasing responsibility, most recently serving as President of Veeder Root. Mr. Hider began his career with General Electric, serving in a number of areas including manufacturing, project management, procurement and finance. He currently serves on the board of directors of Tennant Company (NYSE: TNC).
Patricia B. Morrison

Patricia B. Morrison女士,2009年至2018年,Morrison女士担任全球综合医疗服务和产品公司Cardinal Health Inc.的执行副总裁、客户支持服务和首席信息官。在Cardinal,她领导全球信息技术(IT)业务,包括多个业务部门的转型、收购集成和数字战略。在Cardinal之前,Morrison女士于2008年至2009年是技术咨询公司Maintay Partners的首席执行官。她曾担任摩托罗拉公司和办公仓库公司首席信息官,并在通用电气公司、百事可乐、宝洁公司和贵格燕麦公司担任高级IT职位。她目前担任Splunk Inc.董事,她以前曾担任Aramark公司和Virtusa公司的董事。墨里森女士在俄亥俄牛津迈阿密大学拥有学士学位和学士学位。


Patricia B. Morrison,From 2009 to 2018, Ms. Morrison served as Executive Vice President, Customer Support Services and Chief Information Officer (CIO), of Cardinal Health Inc. (Cardinal), a global, integrated healthcare services and products company. At Cardinal, she led global IT operations, which included the transformation of multiple business segments, acquisition integration and digital strategy. Prior to Cardinal, Ms. Morrison was the Chief Executive Officer of Mainstay Partners, a technology advisory firm, from 2008 to 2009. She previously served as CIO of both Motorola, Inc. and Office Depot, Inc. and held senior-level IT positions at General Electric Company, PepsiCo, Inc., The Procter & Gamble Company and The Quaker Oats Company. She previously served as a director of Splunk Inc. and Virtusa Corporation.
Patricia B. Morrison女士,2009年至2018年,Morrison女士担任全球综合医疗服务和产品公司Cardinal Health Inc.的执行副总裁、客户支持服务和首席信息官。在Cardinal,她领导全球信息技术(IT)业务,包括多个业务部门的转型、收购集成和数字战略。在Cardinal之前,Morrison女士于2008年至2009年是技术咨询公司Maintay Partners的首席执行官。她曾担任摩托罗拉公司和办公仓库公司首席信息官,并在通用电气公司、百事可乐、宝洁公司和贵格燕麦公司担任高级IT职位。她目前担任Splunk Inc.董事,她以前曾担任Aramark公司和Virtusa公司的董事。墨里森女士在俄亥俄牛津迈阿密大学拥有学士学位和学士学位。
Patricia B. Morrison,From 2009 to 2018, Ms. Morrison served as Executive Vice President, Customer Support Services and Chief Information Officer (CIO), of Cardinal Health Inc. (Cardinal), a global, integrated healthcare services and products company. At Cardinal, she led global IT operations, which included the transformation of multiple business segments, acquisition integration and digital strategy. Prior to Cardinal, Ms. Morrison was the Chief Executive Officer of Mainstay Partners, a technology advisory firm, from 2008 to 2009. She previously served as CIO of both Motorola, Inc. and Office Depot, Inc. and held senior-level IT positions at General Electric Company, PepsiCo, Inc., The Procter & Gamble Company and The Quaker Oats Company. She previously served as a director of Splunk Inc. and Virtusa Corporation.
David S. Wilkes

David S. Wilkes自2015年起担任弗吉尼亚大学医学院院长。他曾在印第安纳大学医学院担任越来越负责任的职位,最近担任研究事务执行副主任,并在2009年至2015年间担任August M. Watanabe医学研究教授。Wilkes博士是ImmunewWorks公司的联合创始人。ImmunewWorks是一家生物技术初创公司,自2005年起担任首席科学官。自2006年以来,他一直担任Robert Wood Johnson基金会Harold Amos医学院发展项目的国家主任。这个项目旨在增加在美国主要医学院校中代表性不足的少数民族医生科学家。Wilkes博士是一名退伍军人,曾在美国空军医疗队担任三年少校。2020年,他被选入国家医学院。


David S. Wilkes,served as Dean of the University of Virginia School of Medicine from 2015 to 2021 and currently serves as Dean Emeritus. He previously served in positions of increasing responsibility at Indiana University School of Medicine, most recently as the Executive Associate Director for Research Affairs and as the August M. Watanabe Professor of Medical Research between 2009 and 2015. Dr. Wilkes is the co-founder of ImmuneWorks Inc. (ImmuneWorks), a biotechnology start-up company, and has served as its Chief Scientific Officer since 2005. Since 2006, he has served as the National Director of the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. Dr. Wilkes is a military veteran, having served three years as a major in the U.S. Air Force Medical Corps. In 2020, he was elected to the National Academy of Medicine. Dr. Wilkes previously served as a director of Syneos Health.
David S. Wilkes自2015年起担任弗吉尼亚大学医学院院长。他曾在印第安纳大学医学院担任越来越负责任的职位,最近担任研究事务执行副主任,并在2009年至2015年间担任August M. Watanabe医学研究教授。Wilkes博士是ImmunewWorks公司的联合创始人。ImmunewWorks是一家生物技术初创公司,自2005年起担任首席科学官。自2006年以来,他一直担任Robert Wood Johnson基金会Harold Amos医学院发展项目的国家主任。这个项目旨在增加在美国主要医学院校中代表性不足的少数民族医生科学家。Wilkes博士是一名退伍军人,曾在美国空军医疗队担任三年少校。2020年,他被选入国家医学院。
David S. Wilkes,served as Dean of the University of Virginia School of Medicine from 2015 to 2021 and currently serves as Dean Emeritus. He previously served in positions of increasing responsibility at Indiana University School of Medicine, most recently as the Executive Associate Director for Research Affairs and as the August M. Watanabe Professor of Medical Research between 2009 and 2015. Dr. Wilkes is the co-founder of ImmuneWorks Inc. (ImmuneWorks), a biotechnology start-up company, and has served as its Chief Scientific Officer since 2005. Since 2006, he has served as the National Director of the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. Dr. Wilkes is a military veteran, having served three years as a major in the U.S. Air Force Medical Corps. In 2020, he was elected to the National Academy of Medicine. Dr. Wilkes previously served as a director of Syneos Health.
Jeffrey A. Craig

Jeffrey A. Craig,他是Meritor, Inc.高级副总裁兼总裁,负责商用卡车和工业(2013年2月以来)。他曾担任Meritor, Inc.高级副总裁兼首席财务官(从2009年1月到2013年1月)、总会计师(从2008年5月到2009年1月)、高级副总裁兼总会计师(从2007年7月到2008年5月)、Meritor公司的副总裁和总会计师(从2006年5月到2007年7月),以及GMAC Commercial Finance公司商业金融商业贷款业务的总裁兼首席执行官(从2001年到2006年5月)。


Jeffrey A. Craig,is the former Chief Executive Officer and President of Meritor, Inc. (Meritor), a global supplier of drivetrain, mobility, braking and aftermarket solutions for commercial vehicles, a position he held from 2015 until 2021. Prior to this, from 2014 to 2015, Mr. Craig was President and Chief Operating Officer, with oversight of Meritor's business segments - Commercial Truck & Industrial and Aftermarket & Trailer. Prior to taking on the role of President and Chief Operating Officer, Mr. Craig was Senior Vice President and President of Meritor's Commercial Truck & Industrial segment from 2013 to 2014. He served as Senior Vice President and Chief Financial Officer at Meritor from 2009 to 2013 and held various leadership positions at Meritor since 2006. Before joining Meritor, Mr. Craig served in roles of increasing responsibility at General Motors Acceptance Corporation (GMAC), including as President and Chief Executive Officer of GMAC's Commercial Finance organization and President and Chief Executive Officer of GMAC's Business Credit division. He began his career at Deloitte & Touche, where he served as audit partner. Mr. Craig currently serves as a director of Arcosa, Inc. and Hyliion Holdings Corp.
Jeffrey A. Craig,他是Meritor, Inc.高级副总裁兼总裁,负责商用卡车和工业(2013年2月以来)。他曾担任Meritor, Inc.高级副总裁兼首席财务官(从2009年1月到2013年1月)、总会计师(从2008年5月到2009年1月)、高级副总裁兼总会计师(从2007年7月到2008年5月)、Meritor公司的副总裁和总会计师(从2006年5月到2007年7月),以及GMAC Commercial Finance公司商业金融商业贷款业务的总裁兼首席执行官(从2001年到2006年5月)。
Jeffrey A. Craig,is the former Chief Executive Officer and President of Meritor, Inc. (Meritor), a global supplier of drivetrain, mobility, braking and aftermarket solutions for commercial vehicles, a position he held from 2015 until 2021. Prior to this, from 2014 to 2015, Mr. Craig was President and Chief Operating Officer, with oversight of Meritor's business segments - Commercial Truck & Industrial and Aftermarket & Trailer. Prior to taking on the role of President and Chief Operating Officer, Mr. Craig was Senior Vice President and President of Meritor's Commercial Truck & Industrial segment from 2013 to 2014. He served as Senior Vice President and Chief Financial Officer at Meritor from 2009 to 2013 and held various leadership positions at Meritor since 2006. Before joining Meritor, Mr. Craig served in roles of increasing responsibility at General Motors Acceptance Corporation (GMAC), including as President and Chief Executive Officer of GMAC's Commercial Finance organization and President and Chief Executive Officer of GMAC's Business Credit division. He began his career at Deloitte & Touche, where he served as audit partner. Mr. Craig currently serves as a director of Arcosa, Inc. and Hyliion Holdings Corp.
Brent Shafer

Brent Shafer,他是Cerner的前董事长兼首席执行官,Cerner是各种健康信息技术的领先提供商,从医疗设备到电子健康记录到硬件,从2018年到2021年担任该职位。他将于2023年4月28日起担任首席独立董事。加入Cerner之前,他在Koninklijke Philips NV (Philips)担任多个职位,这是一家健康技术公司,专注于改善人们的健康,从健康生活和预防,到诊断、治疗和家庭护理,包括Philips北美的首席执行官,这是诊断成像、图像引导治疗、患者监测和健康信息以及消费者健康和家庭护理的领导者。他也是飞利浦家庭医疗保健解决方案(飞利浦)业务的首席执行官。在加入Philips之前,他曾担任Hillrom's患者护理环境部门的副总裁兼总经理,并在GE医疗系统公司工作,在那里他担任销售、营销和综合管理的关键职位。他还曾担任Hewlett Packard's Medical Products Group和Johnson & Johnson的高级职位。他目前担任触觉系统技术的董事。


Brent Shafer,became Baxter's Chair of the Board and Interim CEO on February 3, 2025, in connection with Mr. Almeida's departure. He is the former Chair and Chief Executive Officer of Cerner Corporation (Cerner), a leading provider of various health information technologies, ranging from medical devices to electronic health records to hardware, serving in this role from 2018 to 2021. Prior to Cerner, Mr. Shafer held a number of roles at Philips, including Chief Executive Officer of Philips North America. Mr. Shafer was also the Chief Executive Officer of Philips Home Healthcare Solution business. Before joining Philips, Mr. Shafer was Vice President and General Manager of Hillrom's Patient Care Environment Division and worked at GE Medical Systems where he served in key positions in sales, marketing, and general management. Mr. Shafer has also held senior roles at Hewlett Packard's Medical Products Group and Johnson & Johnson. Mr. Shafer currently serves as a director of Tactile Systems Technology, Inc. and Veracyte, Inc.
Brent Shafer,他是Cerner的前董事长兼首席执行官,Cerner是各种健康信息技术的领先提供商,从医疗设备到电子健康记录到硬件,从2018年到2021年担任该职位。他将于2023年4月28日起担任首席独立董事。加入Cerner之前,他在Koninklijke Philips NV (Philips)担任多个职位,这是一家健康技术公司,专注于改善人们的健康,从健康生活和预防,到诊断、治疗和家庭护理,包括Philips北美的首席执行官,这是诊断成像、图像引导治疗、患者监测和健康信息以及消费者健康和家庭护理的领导者。他也是飞利浦家庭医疗保健解决方案(飞利浦)业务的首席执行官。在加入Philips之前,他曾担任Hillrom's患者护理环境部门的副总裁兼总经理,并在GE医疗系统公司工作,在那里他担任销售、营销和综合管理的关键职位。他还曾担任Hewlett Packard's Medical Products Group和Johnson & Johnson的高级职位。他目前担任触觉系统技术的董事。
Brent Shafer,became Baxter's Chair of the Board and Interim CEO on February 3, 2025, in connection with Mr. Almeida's departure. He is the former Chair and Chief Executive Officer of Cerner Corporation (Cerner), a leading provider of various health information technologies, ranging from medical devices to electronic health records to hardware, serving in this role from 2018 to 2021. Prior to Cerner, Mr. Shafer held a number of roles at Philips, including Chief Executive Officer of Philips North America. Mr. Shafer was also the Chief Executive Officer of Philips Home Healthcare Solution business. Before joining Philips, Mr. Shafer was Vice President and General Manager of Hillrom's Patient Care Environment Division and worked at GE Medical Systems where he served in key positions in sales, marketing, and general management. Mr. Shafer has also held senior roles at Hewlett Packard's Medical Products Group and Johnson & Johnson. Mr. Shafer currently serves as a director of Tactile Systems Technology, Inc. and Veracyte, Inc.
William A. Ampofo II

William A. Ampofo II,自2016年以来一直在波音公司工作,目前担任波音全球服务公司的零部件和分销服务业务以及全球服务供应链职能部门的负责人。在此职位上,他领导供应链职能的各个方面,包括在全球70多个国家和300多个地点开展业务的部门。在加入波音公司之前,他在联合技术公司(UTC)工作了22年,担任与财务、信息技术、企业战略和运营相关的职责。他持有Adelphi University的金融学士学位和George Washington University的工商管理硕士学位。他是执行领导委员会的成员,目前担任通用航空制造商协会(General Aviation Manufacturers Association)和达拉斯地区商会(Dallas Regional Chamber)的董事会成员,以及位于康涅狄格州Cheshire的Cheshire Academy的董事会成员。此外,他是霍华德大学供应链管理卓越中心(Center of Excellence In Supply Chain Management)的前顾问委员会成员。


William A. Ampofo II,has worked for Boeing Company (Boeing), a leading global aerospace company, since 2016 and currently serves as Chair, Supply Chain Operations Council and Senior Vice President, Parts & Distribution Services and Supply Chain function for Boeing Global Services. Prior to joining Boeing, he spent 22 years at United Technologies Corporation (which later merged with Raytheon Company to form Raytheon Technologies), a multinational conglomerate which researched, developed, and manufactured products, including aircraft engines, aerospace systems, among other industrial products, working in roles of increasing responsibility related to finance, IT, corporate strategy and operations. Mr. Ampofo currently serves as a member of the board of trustees of The Episcopal School of Dallas.
William A. Ampofo II,自2016年以来一直在波音公司工作,目前担任波音全球服务公司的零部件和分销服务业务以及全球服务供应链职能部门的负责人。在此职位上,他领导供应链职能的各个方面,包括在全球70多个国家和300多个地点开展业务的部门。在加入波音公司之前,他在联合技术公司(UTC)工作了22年,担任与财务、信息技术、企业战略和运营相关的职责。他持有Adelphi University的金融学士学位和George Washington University的工商管理硕士学位。他是执行领导委员会的成员,目前担任通用航空制造商协会(General Aviation Manufacturers Association)和达拉斯地区商会(Dallas Regional Chamber)的董事会成员,以及位于康涅狄格州Cheshire的Cheshire Academy的董事会成员。此外,他是霍华德大学供应链管理卓越中心(Center of Excellence In Supply Chain Management)的前顾问委员会成员。
William A. Ampofo II,has worked for Boeing Company (Boeing), a leading global aerospace company, since 2016 and currently serves as Chair, Supply Chain Operations Council and Senior Vice President, Parts & Distribution Services and Supply Chain function for Boeing Global Services. Prior to joining Boeing, he spent 22 years at United Technologies Corporation (which later merged with Raytheon Company to form Raytheon Technologies), a multinational conglomerate which researched, developed, and manufactured products, including aircraft engines, aerospace systems, among other industrial products, working in roles of increasing responsibility related to finance, IT, corporate strategy and operations. Mr. Ampofo currently serves as a member of the board of trustees of The Episcopal School of Dallas.
Amy A. Wendell

Amy A. Wendell,将因此次分配而被任命为Solventum Corporation董事会成员。2016年至2019年担任Perella Weinberg合伙人医疗健康投资银行业务高级顾问。从2015年到2018年9月,Wendell女士担任麦肯锡战略和企业融资业务的高级顾问,还担任麦肯锡交易咨询委员会的成员,帮助确定并购趋势,并帮助塑造麦肯锡的知识议程。从1986年到2015年1月,Wendell女士在Covidien plc(包括其前身Tyco Healthcare和Kendall Healthcare Products)担任过越来越多的职务,包括工程、产品管理和业务发展。从2006年12月到2015年1月Covidien被美敦力 PLC收购,她担任战略和业务发展高级副总裁,领导公司的战略和投资组合管理计划,并管理所有业务发展,包括收购、股权投资、资产剥离和许可/分销。Wendell女士担任AxoGen,Inc.的首席董事,担任提名和治理委员会以及审计委员会成员;在百特国际,Inc.的董事会担任质量、合规和技术委员会以及薪酬和人力资本委员会成员;在Hologic, Inc.的董事会担任审计和财务委员会成员。她还担任Por Cristo的董事会成员,Por Cristo是一家非营利慈善医疗服务组织,参与拉丁美洲高危妇女和儿童的医疗保健工作。Wendell女士拥有劳伦斯理工大学机械工程理学学士学位和伊利诺伊大学生物医学工程理学硕士学位。


Amy A. Wendell,Perella Weinberg Partners:Senior Advisor, Healthcare Investment Banking (2016 – 2019);McKinsey & Company:Senior Advisor, Strategy and Corporation Finance (2015 – 2018);Covidien plc:Senior Vice President of Strategy and Business Development (2006 – 2015).
Amy A. Wendell,将因此次分配而被任命为Solventum Corporation董事会成员。2016年至2019年担任Perella Weinberg合伙人医疗健康投资银行业务高级顾问。从2015年到2018年9月,Wendell女士担任麦肯锡战略和企业融资业务的高级顾问,还担任麦肯锡交易咨询委员会的成员,帮助确定并购趋势,并帮助塑造麦肯锡的知识议程。从1986年到2015年1月,Wendell女士在Covidien plc(包括其前身Tyco Healthcare和Kendall Healthcare Products)担任过越来越多的职务,包括工程、产品管理和业务发展。从2006年12月到2015年1月Covidien被美敦力 PLC收购,她担任战略和业务发展高级副总裁,领导公司的战略和投资组合管理计划,并管理所有业务发展,包括收购、股权投资、资产剥离和许可/分销。Wendell女士担任AxoGen,Inc.的首席董事,担任提名和治理委员会以及审计委员会成员;在百特国际,Inc.的董事会担任质量、合规和技术委员会以及薪酬和人力资本委员会成员;在Hologic, Inc.的董事会担任审计和财务委员会成员。她还担任Por Cristo的董事会成员,Por Cristo是一家非营利慈善医疗服务组织,参与拉丁美洲高危妇女和儿童的医疗保健工作。Wendell女士拥有劳伦斯理工大学机械工程理学学士学位和伊利诺伊大学生物医学工程理学硕士学位。
Amy A. Wendell,Perella Weinberg Partners:Senior Advisor, Healthcare Investment Banking (2016 – 2019);McKinsey & Company:Senior Advisor, Strategy and Corporation Finance (2015 – 2018);Covidien plc:Senior Vice President of Strategy and Business Development (2006 – 2015).
Michael R. McDonnell

Michael R. McDonnell,曾担任Biogen Inc.的董事。自2020年8月起担任执行副总裁兼首席财务官。在加入Biogen之前,McDonnell先生从2015年12月到2020年7月担任IQVIA Holdings Inc.的执行副总裁兼首席财务官,IQVIA Holdings Inc.是全球领先的生命科学行业高级分析、技术解决方案和合同研究服务提供商。此前,2008年11月至2015年12月,他担任全球领先的卫星服务提供商Intelsat的执行副总裁兼首席财务官;2004年9月至2008年10月,担任上市商业金融公司MCG Capital Corporation的执行副总裁兼首席财务官;2006年8月至2008年10月,担任MCG Capital Corporation的首席运营官。在加入MCG Capital Corporation之前,从2004年7月到2004年8月,McDonnell先生担任EchoStar Communications Corporation(一家直接到家庭的卫星电视运营商)的执行副总裁兼首席财务官;从2000年8月到2004年7月,担任其高级副总裁兼首席财务官。McDonnell先生在PricewaterhouseCoopers LLP工作了14年,其中4年担任合伙人。他是一名注册会计师(CPA)。


Michael R. McDonnell,has served as Executive Vice President and Chief Financial Officer of Biogen since August 2020. Previously, he was EVP and CFO of IQVIA Holdings Inc. (2015-2020) and EVP and CFO of Intelsat (2008-2015). His earlier roles include EVP/CFO and COO of MCG Capital Corporation (2004-2008), and senior financial leadership positions at EchoStar Communications Corporation (2000-2004). He began his career with 14 years at PricewaterhouseCoopers LLP, including 4 years as partner. A licensed CPA, he serves on the board of Merit Medical Systems, Inc. and holds a B.S. in Accounting from Georgetown University.
Michael R. McDonnell,曾担任Biogen Inc.的董事。自2020年8月起担任执行副总裁兼首席财务官。在加入Biogen之前,McDonnell先生从2015年12月到2020年7月担任IQVIA Holdings Inc.的执行副总裁兼首席财务官,IQVIA Holdings Inc.是全球领先的生命科学行业高级分析、技术解决方案和合同研究服务提供商。此前,2008年11月至2015年12月,他担任全球领先的卫星服务提供商Intelsat的执行副总裁兼首席财务官;2004年9月至2008年10月,担任上市商业金融公司MCG Capital Corporation的执行副总裁兼首席财务官;2006年8月至2008年10月,担任MCG Capital Corporation的首席运营官。在加入MCG Capital Corporation之前,从2004年7月到2004年8月,McDonnell先生担任EchoStar Communications Corporation(一家直接到家庭的卫星电视运营商)的执行副总裁兼首席财务官;从2000年8月到2004年7月,担任其高级副总裁兼首席财务官。McDonnell先生在PricewaterhouseCoopers LLP工作了14年,其中4年担任合伙人。他是一名注册会计师(CPA)。
Michael R. McDonnell,has served as Executive Vice President and Chief Financial Officer of Biogen since August 2020. Previously, he was EVP and CFO of IQVIA Holdings Inc. (2015-2020) and EVP and CFO of Intelsat (2008-2015). His earlier roles include EVP/CFO and COO of MCG Capital Corporation (2004-2008), and senior financial leadership positions at EchoStar Communications Corporation (2000-2004). He began his career with 14 years at PricewaterhouseCoopers LLP, including 4 years as partner. A licensed CPA, he serves on the board of Merit Medical Systems, Inc. and holds a B.S. in Accounting from Georgetown University.
Nancy M. Schlichting

Nancy M. Schlichting在Baxter收购Hillrom后加入董事会,她此前曾担任董事兼薪酬和管理发展委员会主席。Schlichting女士是密歇根州底特律Henry Ford Health System(HFHS)的退休总裁兼首席执行官,Henry Ford Health System是一家非营利性医疗保健组织,于2003年6月至2017年1月担任该职务。她于1998年加入HFHS,担任高级副总裁兼首席行政官,1999年至2003年晋升为执行副总裁兼首席运营官,2001年至2003年晋升为Henry Ford医院总裁兼首席执行官。她目前担任Walgreens Boots Alliance和Encompass Health, Inc.的董事,并担任杜克大学受托人和杜克大学健康系统董事会主席。她此前曾担任Pear Therapeutics,Inc.的董事和Kresge基金会的受托人。


Nancy M. Schlichting,joined the Board in 2021 following Baxter's acquisition of Hill-Rom Holdings, Inc. (Hillrom), where she had previously served as a director and Chair of its Compensation and Management Development Committee. Ms. Schlichting is the retired President and Chief Executive Officer of Henry Ford Health System (HFHS) in Detroit, Michigan, a non-profit healthcare organization, serving in this role from June 2003 to January 2017. She joined HFHS in 1998 as Senior Vice President and Chief Administrative Officer and served as Executive Vice President and Chief Operating Officer from 1999 to 2003 and as President and Chief Executive Officer of Henry Ford Hospital from 2001 to 2003. She currently serves as a director of Encompass Health, Inc. and Walgreens Boots Alliance, and as a trustee of the Duke University and as the chair of the Duke University Health System Board. She previously served as a director of Pear Therapeutics, Inc. and as a trustee of the Kresge Foundation.
Nancy M. Schlichting在Baxter收购Hillrom后加入董事会,她此前曾担任董事兼薪酬和管理发展委员会主席。Schlichting女士是密歇根州底特律Henry Ford Health System(HFHS)的退休总裁兼首席执行官,Henry Ford Health System是一家非营利性医疗保健组织,于2003年6月至2017年1月担任该职务。她于1998年加入HFHS,担任高级副总裁兼首席行政官,1999年至2003年晋升为执行副总裁兼首席运营官,2001年至2003年晋升为Henry Ford医院总裁兼首席执行官。她目前担任Walgreens Boots Alliance和Encompass Health, Inc.的董事,并担任杜克大学受托人和杜克大学健康系统董事会主席。她此前曾担任Pear Therapeutics,Inc.的董事和Kresge基金会的受托人。
Nancy M. Schlichting,joined the Board in 2021 following Baxter's acquisition of Hill-Rom Holdings, Inc. (Hillrom), where she had previously served as a director and Chair of its Compensation and Management Development Committee. Ms. Schlichting is the retired President and Chief Executive Officer of Henry Ford Health System (HFHS) in Detroit, Michigan, a non-profit healthcare organization, serving in this role from June 2003 to January 2017. She joined HFHS in 1998 as Senior Vice President and Chief Administrative Officer and served as Executive Vice President and Chief Operating Officer from 1999 to 2003 and as President and Chief Executive Officer of Henry Ford Hospital from 2001 to 2003. She currently serves as a director of Encompass Health, Inc. and Walgreens Boots Alliance, and as a trustee of the Duke University and as the chair of the Duke University Health System Board. She previously served as a director of Pear Therapeutics, Inc. and as a trustee of the Kresge Foundation.

高管简历

中英对照 |  中文 |  英文
Andrew P. Hider

Andrew P. Hider,他是ATS Corporation (TSX和NYSE: ATS)的首席执行官和董事会成员,分别自2017年3月和2017年5月担任该职位。此前,他曾担任Taylor Made Group, LLC的总裁兼首席执行官(2016年5月至2017年2月)。在此之前,他曾在Danaher Corporation任职10年,担任越来越重要的职务,最近担任Veeder Root的总裁。他的职业生涯始于General Electric,任职于多个领域,包括制造、项目管理、采购和财务。他目前还担任Tennant Company的董事会成员。他获得Clarkson大学的跨学科工程与管理学士学位和工商管理硕士学位。


Andrew P. Hider is President and Chief Executive Officer and a member of the Board of Directors of Baxter. He was appointed on Augt 19, 2025. Additionally, he was appointed as Interim Group President, Medical Products & Therapies, in October 2025 and served in that interim capacity until December 2025. Before joining Baxter, he served as Chief Executive Officer and a member of the board of directors of ATS Corporation, roles which he has held since March 2017 and May 2017, respectively. Previoly, Mr. Hider served as President and Chief Executive Officer of the Taylor Made Group, LLC, from May 2016 to February 2017. Prior to that, Mr. Hider served for ten years at Danaher Corporation, working in roles of increasing responsibility, most recently serving as President of Veeder Root. Mr. Hider began his career with General Electric, serving in a number of areas including manufacturing, project management, procurement and finance. He currently serves on the board of directors of Tennant Company (NYSE: TNC).
Andrew P. Hider,他是ATS Corporation (TSX和NYSE: ATS)的首席执行官和董事会成员,分别自2017年3月和2017年5月担任该职位。此前,他曾担任Taylor Made Group, LLC的总裁兼首席执行官(2016年5月至2017年2月)。在此之前,他曾在Danaher Corporation任职10年,担任越来越重要的职务,最近担任Veeder Root的总裁。他的职业生涯始于General Electric,任职于多个领域,包括制造、项目管理、采购和财务。他目前还担任Tennant Company的董事会成员。他获得Clarkson大学的跨学科工程与管理学士学位和工商管理硕士学位。
Andrew P. Hider is President and Chief Executive Officer and a member of the Board of Directors of Baxter. He was appointed on Augt 19, 2025. Additionally, he was appointed as Interim Group President, Medical Products & Therapies, in October 2025 and served in that interim capacity until December 2025. Before joining Baxter, he served as Chief Executive Officer and a member of the board of directors of ATS Corporation, roles which he has held since March 2017 and May 2017, respectively. Previoly, Mr. Hider served as President and Chief Executive Officer of the Taylor Made Group, LLC, from May 2016 to February 2017. Prior to that, Mr. Hider served for ten years at Danaher Corporation, working in roles of increasing responsibility, most recently serving as President of Veeder Root. Mr. Hider began his career with General Electric, serving in a number of areas including manufacturing, project management, procurement and finance. He currently serves on the board of directors of Tennant Company (NYSE: TNC).
James Borzi

James Borzi,他于2020年8月从GE Healthcare加入Baxter,并在2019年至2020年间担任副总裁兼首席供应链官。在加入GE Healthcare之前,他曾在Becton Dickinson BD担任过五年的制造运营领导职务;他在BD的最后一个职务是全球运营执行副总裁兼首席供应链官。在其职业生涯早期,他曾任Hydro Aluminum运营与技术高级副总裁和Lennox International全球运营执行副总裁。在此之前,他是AEES的首席运营官和美国铝业负责美洲业务的高级副总裁。


James Borzi,is Executive Vice President and Chief Supply Chain Officer. He joined Baxter in August 2020 from GE Healthcare, where he served as Vice President, Chief Supply Chain Officer from 2019 to 2020. Prior to joining GE Healthcare, he served in various manufacturing operations leadership roles at Becton Dickinson (BD), including Executive Vice President of Global Operations and Chief Supply Chain Officer from 2013 to 2019. Earlier in his career, he was Senior Vice President of Operations & Technology at Hydro Aluminum and Executive Vice President of Worldwide Operations at Lennox International. Prior to that, he was the Chief Operating Officer at AEES Inc. and Senior Vice President of Americas Operations at Alcoa Corporation. Mr. Borzi is a senior advisor to the NAI Group, a Pritzker Private Capital company.
James Borzi,他于2020年8月从GE Healthcare加入Baxter,并在2019年至2020年间担任副总裁兼首席供应链官。在加入GE Healthcare之前,他曾在Becton Dickinson BD担任过五年的制造运营领导职务;他在BD的最后一个职务是全球运营执行副总裁兼首席供应链官。在其职业生涯早期,他曾任Hydro Aluminum运营与技术高级副总裁和Lennox International全球运营执行副总裁。在此之前,他是AEES的首席运营官和美国铝业负责美洲业务的高级副总裁。
James Borzi,is Executive Vice President and Chief Supply Chain Officer. He joined Baxter in August 2020 from GE Healthcare, where he served as Vice President, Chief Supply Chain Officer from 2019 to 2020. Prior to joining GE Healthcare, he served in various manufacturing operations leadership roles at Becton Dickinson (BD), including Executive Vice President of Global Operations and Chief Supply Chain Officer from 2013 to 2019. Earlier in his career, he was Senior Vice President of Operations & Technology at Hydro Aluminum and Executive Vice President of Worldwide Operations at Lennox International. Prior to that, he was the Chief Operating Officer at AEES Inc. and Senior Vice President of Americas Operations at Alcoa Corporation. Mr. Borzi is a senior advisor to the NAI Group, a Pritzker Private Capital company.
David S. Rosenbloom

David S. Rosenbloom是高级副总裁兼总法律顾问。Rosenbloom先生从McDermott Will & Emery(McDermott)加入Baxter,在那里他担任了24年的合伙人,并于2017年至2022年担任诉讼业务组的全球主管。在加入McDermott之前,他曾在美国伊利诺伊州北区检察官办公室任职八年。Rosenbloom先生是消化健康基金会的董事会成员,该基金会支持西北消化健康中心的研究,该中心是西北纪念医院西北医学的一部分。


David S. Rosenbloom is Executive Vice President and General Counsel. Mr. Rosenbloom joined Baxter from McDermott Will & Schultz, formerly known as McDermott Will & Emery (McDermott), where he served as a partner for 24 years and Global Head of the Litigation Practice Group from 2017 to 2022. Prior to McDermott, he served for eight years in the U.S. Attorney's Office for the Northern District of Illinois. Mr. Rosenbloom is a member of the advisory counsel of the Digestive Health Institute.
David S. Rosenbloom是高级副总裁兼总法律顾问。Rosenbloom先生从McDermott Will & Emery(McDermott)加入Baxter,在那里他担任了24年的合伙人,并于2017年至2022年担任诉讼业务组的全球主管。在加入McDermott之前,他曾在美国伊利诺伊州北区检察官办公室任职八年。Rosenbloom先生是消化健康基金会的董事会成员,该基金会支持西北消化健康中心的研究,该中心是西北纪念医院西北医学的一部分。
David S. Rosenbloom is Executive Vice President and General Counsel. Mr. Rosenbloom joined Baxter from McDermott Will & Schultz, formerly known as McDermott Will & Emery (McDermott), where he served as a partner for 24 years and Global Head of the Litigation Practice Group from 2017 to 2022. Prior to McDermott, he served for eight years in the U.S. Attorney's Office for the Northern District of Illinois. Mr. Rosenbloom is a member of the advisory counsel of the Digestive Health Institute.
Reazur Rasul

Reazur Rasul是医疗保健系统与技术执行副总裁兼集团总裁。自2022年起担任前线护理总裁后,他于2023年被任命为现职。在此之前,Rasul先生曾于2021年至2022年担任急性疗法和给药业务总经理,并于2017年至2021年担任急性疗法业务总经理。在2017年加入Baxter之前,他曾在惠普企业 Enterprise工作,担任副总裁兼全球云基础设施业务总经理。此前,他曾在GE Healthcare工作,在那里他担任过几个在业务领导和战略方面日益增加的职责,包括全球介入心脏病学业务总经理。Rasul先生的职业生涯始于Toyota Motor Corporation,最终在战略、产品开发和运营方面担任多个领导职务。


Reazur Rasul is Executive Vice President and Group President, Healthcare Systems & Technologies. He was appointed to his current role in 2023 after serving as President of Front Line Care since 2022. Prior to that, Mr. Rasul served as General Manager for the Acute Therapies & Medication Delivery binesses from 2021 to 2022, and General Manager for the Acute Therapies biness from 2017 to 2021. Before joining Baxter in 2017, he worked with Hewlett Packard Enterprise where he was Vice President and General Manager of the Global Cloud infrastructure biness. Previoly, he worked with GE Healthcare where he held several roles of increasing responsibility in biness leadership and strategy, including General Manager of the Global Interventional Cardiology biness. Mr. Rasul began his professional career with Toyota Motor Corporation and ultimately held multiple leadership positions in strategy, product development, and operations.
Reazur Rasul是医疗保健系统与技术执行副总裁兼集团总裁。自2022年起担任前线护理总裁后,他于2023年被任命为现职。在此之前,Rasul先生曾于2021年至2022年担任急性疗法和给药业务总经理,并于2017年至2021年担任急性疗法业务总经理。在2017年加入Baxter之前,他曾在惠普企业 Enterprise工作,担任副总裁兼全球云基础设施业务总经理。此前,他曾在GE Healthcare工作,在那里他担任过几个在业务领导和战略方面日益增加的职责,包括全球介入心脏病学业务总经理。Rasul先生的职业生涯始于Toyota Motor Corporation,最终在战略、产品开发和运营方面担任多个领导职务。
Reazur Rasul is Executive Vice President and Group President, Healthcare Systems & Technologies. He was appointed to his current role in 2023 after serving as President of Front Line Care since 2022. Prior to that, Mr. Rasul served as General Manager for the Acute Therapies & Medication Delivery binesses from 2021 to 2022, and General Manager for the Acute Therapies biness from 2017 to 2021. Before joining Baxter in 2017, he worked with Hewlett Packard Enterprise where he was Vice President and General Manager of the Global Cloud infrastructure biness. Previoly, he worked with GE Healthcare where he held several roles of increasing responsibility in biness leadership and strategy, including General Manager of the Global Interventional Cardiology biness. Mr. Rasul began his professional career with Toyota Motor Corporation and ultimately held multiple leadership positions in strategy, product development, and operations.
Anita Zielinski

Anita Zielinski,从Sysco加入公司,她曾在Sysco工作了七年,最近一次是从2022年开始,担任美国餐饮服务运营部门高级副总裁兼首席财务官,负责Sysco美国业务部门的财务监督。在此之前,她于2017年至2022年担任Sysco的高级副总裁兼首席会计官。在加入Sysco之前,她是安永会计师事务所的审计合伙人。Zielinski女士拥有得克萨斯农工大学工商管理学士学位,是得克萨斯州持牌注册会计师。


Anita Zielinski Anita Zielinski, 52, joined the Company in 2025 as Senior Vice President, Chief Accounting Officer and Controller. Before joining the Company, she worked for Sysco Corporation ("Sysco") for seven years, most recently, beginning in 2022, as the Senior Vice President and Chief Financial Officer, Foodservice Operations, and prior to that as Senior Vice President and Chief Accounting Officer. Prior to Sysco, Ms. Zielinski spent more than 20 years at Ernst & Young LLP, including as an audit partner.
Anita Zielinski,从Sysco加入公司,她曾在Sysco工作了七年,最近一次是从2022年开始,担任美国餐饮服务运营部门高级副总裁兼首席财务官,负责Sysco美国业务部门的财务监督。在此之前,她于2017年至2022年担任Sysco的高级副总裁兼首席会计官。在加入Sysco之前,她是安永会计师事务所的审计合伙人。Zielinski女士拥有得克萨斯农工大学工商管理学士学位,是得克萨斯州持牌注册会计师。
Anita Zielinski Anita Zielinski, 52, joined the Company in 2025 as Senior Vice President, Chief Accounting Officer and Controller. Before joining the Company, she worked for Sysco Corporation ("Sysco") for seven years, most recently, beginning in 2022, as the Senior Vice President and Chief Financial Officer, Foodservice Operations, and prior to that as Senior Vice President and Chief Accounting Officer. Prior to Sysco, Ms. Zielinski spent more than 20 years at Ernst & Young LLP, including as an audit partner.
Maria Cecilia Soriano

Maria Cecilia Soriano集团总裁,Infion Therapies & Technologies & Pharmaceuticals。Soriano女士自2023年起担任Infion Therapies & Technologies总裁后,于2025年被任命为现职。在加入Baxter之前,Soriano女士曾在Becton Dickinson and Company担任越来越多的职责,包括2020年至2023年担任全球副总裁兼微生物学总经理;美国副总裁兼糖尿病护理总经理;全球营销和战略高级副总裁;战略营销副总裁。Previoly,她曾在可口可乐公司强生和花旗银行工作。Soriano女士目前担任ScionHealth董事会成员。


Maria Cecilia Soriano s Group President, Infion Therapies & Technologies & Pharmaceuticals. Ms. Soriano was appointed to her current role in 2025 after serving as President, Infion Therapies & Technologies since 2023. Prior to joining Baxter, Ms. Soriano served in increasing roles of responsibility at Becton Dickinson and Company, including as Global Vice President, General Manager, Microbiology from 2020 to 2023; U.S. Vice President, General Manager, Diabetes Care; Senior Vice President, Global Marketing and Strategy; and Vice President, Strategic Marketing. Previoly, she worked at Johnson & Johnson, the Coca Cola Company and Citibank, N.A. Ms. Soriano currently serves as a member of the board of directors of ScionHealth.
Maria Cecilia Soriano集团总裁,Infion Therapies & Technologies & Pharmaceuticals。Soriano女士自2023年起担任Infion Therapies & Technologies总裁后,于2025年被任命为现职。在加入Baxter之前,Soriano女士曾在Becton Dickinson and Company担任越来越多的职责,包括2020年至2023年担任全球副总裁兼微生物学总经理;美国副总裁兼糖尿病护理总经理;全球营销和战略高级副总裁;战略营销副总裁。Previoly,她曾在可口可乐公司强生和花旗银行工作。Soriano女士目前担任ScionHealth董事会成员。
Maria Cecilia Soriano s Group President, Infion Therapies & Technologies & Pharmaceuticals. Ms. Soriano was appointed to her current role in 2025 after serving as President, Infion Therapies & Technologies since 2023. Prior to joining Baxter, Ms. Soriano served in increasing roles of responsibility at Becton Dickinson and Company, including as Global Vice President, General Manager, Microbiology from 2020 to 2023; U.S. Vice President, General Manager, Diabetes Care; Senior Vice President, Global Marketing and Strategy; and Vice President, Strategic Marketing. Previoly, she worked at Johnson & Johnson, the Coca Cola Company and Citibank, N.A. Ms. Soriano currently serves as a member of the board of directors of ScionHealth.
Jeanne K. Mason

Jeanne K. Mason于2006年从通用电气保险解决方案公司(GE Insurance Solutions)加入巴克斯特,这是一家主要的保险和再保险业务,负责全球人力资源职能。1988年,梅森女士在华盛顿特区的美国总会计师事务所(U.S.General Accounting Office)任职后,开始了在通用电气(General Electric GE)的职业生涯。她的通用电气经验包括在欧洲担任通用电气信息服务公司(GE Information Services)和通用电气金融房地产公司(GE Capital Real Estate)的领导职务。她是莱克县家庭服务董事会成员,也是全国非裔美国人人力资源协会芝加哥分会执行咨询委员会成员。


Jeanne K. Mason,is Executive Vice President and Chief Human Resources Officer having served in that capacity since 2006. Ms. Mason joined Baxter in 2006 from GE Insurance Solutions, a primary insurance and reinsurance business, where she was responsible for global human resource functions. Ms. Mason began her career with General Electric (GE) in 1988 after serving with the U.S. General Accounting Office in Washington, D.C. Her GE experience included leadership roles in Europe for GE Information Services and GE Capital Real Estate. She is a member of the Board of Directors of Family Service of Lake County and is a member of the Executive Advisory Council for the Chicago Chapter of National Association of African Americans in Human Resources.
Jeanne K. Mason于2006年从通用电气保险解决方案公司(GE Insurance Solutions)加入巴克斯特,这是一家主要的保险和再保险业务,负责全球人力资源职能。1988年,梅森女士在华盛顿特区的美国总会计师事务所(U.S.General Accounting Office)任职后,开始了在通用电气(General Electric GE)的职业生涯。她的通用电气经验包括在欧洲担任通用电气信息服务公司(GE Information Services)和通用电气金融房地产公司(GE Capital Real Estate)的领导职务。她是莱克县家庭服务董事会成员,也是全国非裔美国人人力资源协会芝加哥分会执行咨询委员会成员。
Jeanne K. Mason,is Executive Vice President and Chief Human Resources Officer having served in that capacity since 2006. Ms. Mason joined Baxter in 2006 from GE Insurance Solutions, a primary insurance and reinsurance business, where she was responsible for global human resource functions. Ms. Mason began her career with General Electric (GE) in 1988 after serving with the U.S. General Accounting Office in Washington, D.C. Her GE experience included leadership roles in Europe for GE Information Services and GE Capital Real Estate. She is a member of the Board of Directors of Family Service of Lake County and is a member of the Executive Advisory Council for the Chicago Chapter of National Association of African Americans in Human Resources.